A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer

Oncologist

Volumn 15, Issue 8, 2010, Pages 845-851

  Willett, Christopher G ^a   Duda, Dan G ^b   Ancukiewicz, Marek ^b   Shah, Mira ^a   Czito, Brian G ^a   Bentley, Rex ^a   Poleski, Martin ^a   Fujita, Hiroshi ^b   Lauwers, Gregory Y ^b   Carroll, Madeline ^a   Tyler, Douglas ^a   Mantyh, Christopher ^a   Shellito, Paul ^b   Chung, Daniel C ^b   Clark, Jeffrey W ^b   Jain, Rakesh K ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bevacizumab; Chemoradiation; Neoadjuvant; Rectal cancer; Toxicity

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ABDOMINAL ABSCESS; ADJUVANT THERAPY; ANASTOMOSIS LEAKAGE; ANOREXIA; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; ENTEROCUTANEOUS FISTULA; EXTERNAL BEAM RADIOTHERAPY; FISTULA; HAND FOOT SYNDROME; HEMATOMA; HUMAN; HYPERTENSION; ILEUS; INFECTION; KIDNEY FAILURE; LIVER METASTASIS; LIVER RESECTION; LUNG EDEMA; LUNG EMBOLISM; LYMPH NODE METASTASIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROGENIC BLADDER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PELVIC BLEEDING; PELVIC DISEASE; PELVIS BLEEDING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTALGIA; PROCTITIS; RADIATION DERMATITIS; RECTOVAGINAL FISTULA; RECTUM CANCER; RECTUM SURGERY; SEPSIS; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; TREATMENT OUTCOME; TUMOR VOLUME; URINARY FREQUENCY; URINARY URGENCY; URINE RETENTION; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT; WOUND INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES; RECTAL NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77955042029     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0030     Document Type: Article

References (17)

1. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative hemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740.
2. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-1544.
3. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
4. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-4380.
5. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
6. Jain RK, Duda DG, Clark JW et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40.
7. Crane CH, Eng C, Feig BW et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer [abstract 4091]. Int J Radiat Oncol Biol Phys 2010;76:824-830.
8. DiPetrillo TA, Pricolo V, Sikov WM et al. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation in clinical stage II-III rectal cancer. J Clin Oncol 2008;26(15 suppl):15041.
9. Willett CG, Duda DG, di Tomaso E et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase II study. J Clin Oncol 2009;27:3020-3026.
10. Ebos JM, Lee CR, Cruz-Munoz W et al. Accelerated metastasis after shortterm treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-239.
11. Loges S, Mazzone M, Hohensinner P et al. Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell 2009;15: 167-170.
12. Pàez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231.
13. Padera TP, Kuo AH, Hoshida T et al. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Ther 2008;7:2272-2279.
14. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGFspecific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.
15. Willett CG, Boucher Y, Duda DG et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23:8136-8139.
16. Wolmark N, Yothers G, O'Connell MG et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J Clin Oncol 2009;27(18 suppl):LBA4.
17. Duda DG, Willett CG, Ancukiewicz M et al. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. The Oncologist 2010;15: 577-583.